Adolescent girls' preferences for HPV vaccines: A discrete choice experiment

Advances in Health Economics and Health Services Research

Volumn 24, Issue , 2014, Pages 93-121

  Brown, Derek S ^a   Poulos, Christine ^a   Johnson, F Reed ^a   Chamiec Case, Linda ^a   Messonnier, Mark L ^a  

^a NONE

Author keywords

Conjoint analysis; Discrete choice experiment; Human papillomavirus vaccine; Latent class

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADOLESCENT HEALTH; ARTICLE; AWARENESS; CANCER PREVENTION; CONDYLOMA ACUMINATUM; DRUG PREFERENCE; DRUG UPTAKE; EXPERIMENTAL STUDY; FACE VALIDITY; FEMALE; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; INCOME; MEDICAL DECISION MAKING; NORMAL HUMAN; PRACTICE GUIDELINE; PUBLIC HEALTH; RISK FACTOR; SEXUAL BEHAVIOR; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; DECISION MAKING; ECONOMICS; MALE; PATIENT PREFERENCE; QUESTIONNAIRE; THEORETICAL MODEL; UTERINE CERVIX TUMOR;

ADOLESCENT; CHOICE BEHAVIOR; FEMALE; HUMANS; MALE; MODELS, THEORETICAL; PAPILLOMAVIRUS VACCINES; PATIENT PREFERENCE; QUESTIONNAIRES; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 84908326857     PISSN: 07312199     EISSN: None     Source Type: Book Series    
DOI: 10.1108/S0731-219920140000024002     Document Type: Article

References (66)

1. Alphs, H. H., Gambhira, R., Karanam, B., Roberts, J. N., Jagu, S., Schiller, J. T. et al. (2008). Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proceedings of the National Academy of Sciences, 105, 5850-5855.
2. Bair, R. M., and Mays, R. M., Sturm, L. A., Perkins, S. M., and Juliar, B. E., & Zimet, G. D. (2008). Acceptability to Latino parents of sexually transmitted infection vaccination. Ambulatory Pediatrics, 8, 98-103.
3. Bosch, F. X., and Burchell, A. N., Schiffman, M., Giuliano, A. R., de Sanjose, S., Bruni, L., Muñoz, N. (2008). Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine, 26(Suppl. 10), K1-K16.
4. Bosch, F. X., & de Sanjose, S. (2003). Human papillomavirus and cervical cancer - Burden and assessment of causality. Journal of the National Cancer Institute Monographs, 31, 3-13.
5. Brewer, N. T., & Fazekas, K. I. (2007). Predictors of HPV vaccine acceptability: A theory-informed, systematic review. Preventive Medicine, 45, 107-114.
6. Brisson, M., Boily, M.-C., De Wals, P., & Van de Velde, N. (2007). The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine, 25(29), 5399-5408.
7. Brody, J. L., and Annett, R. D., Scherer, D. G., Perryman, M. L., & Cofrin, K. M. (2005). Comparisons of adolescent and parent willingness to participate in minimal and above-minimal risk pediatric asthma research protocols. Journal of Adolescent Health, 37, 229-235.
8. Brotherton, J. M. L., Fridman, M., May, C. L., Chapell, G., and Saville, A. M., & Gertig, D. M. (2011). Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: An ecological study. Lancet, 377, 2085-2092.
9. Brown, D. S., and Finkelstein, E. A., Brown, D. R., Buchner, D. M., & Johnson, F. R. (2009). Estimating older adults' preferences for walking programs via conjoint analysis. American Journal of Preventive Medicine, 36, 201-207.
10. Brown, D. S., and Johnson, F. R., Poulos, C., & Messonnier, M. L. (2010). Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus. Vaccine, 28, 1702-1708.
11. Centers for Disease Control and Prevention. (2010). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 59, 626-629.
12. Centers for Disease Control and Prevention. (2011). Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report, 60, 1705-1708.
13. Centers for Disease Control and Prevention. (2012). National, state, and local area vaccination coverage among adolescents aged 13-17 years - United States, 2011. Morbidity and Mortality Weekly Report, 61, 671-677.
14. Centers for Disease Control and Prevention. (2013). HPV vaccine information for young women. Retrieved from http://www.cdc.gov/std/hpv/STDFact-HPV-vaccine-young-women.htm
15. Chaturvedi, A. K. (2010). Beyond cervical cancer: Burden of other HPV-related cancers among men and women. Journal of Adolescent Health, 46, S20-S26.
16. Chesson, H. W., and Blandford, J. M., Gift, T. L., Tao, G., & Irwin, K. L. (2004). The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspectives on Sexual and Reproductive Health, 36, 11-19.
17. Christian, W. J., Christian, A., & Hopenhayn, C. (2009). Acceptance of the HPV vaccine for adolescent girls: Analysis of state-added questions from the BRFSS. Journal of Adolescent Health, 44, 437-445.
18. de Bekker-Grob, E. W., Hofman, R., Donkers, B., van Ballegooijen, M., Helmerhorst, T. J., Raat, H., Korfage, I. J. (2010). Girls' preferences for HPV vaccination: A discrete choice experiment. Vaccine, 28, 6692-6697.
19. DeNavas-Walt, C., Proctor, B. D., & Smith, J. C. (2012). Income, poverty, and health insurance coverage in the United States: 2011. U.S. Census Bureau Current Population Reports, P60-243, U.S. Government Printing Office, Washington, DC.
20. Dennis, J. M. (2012). Summary of Knowledge Panel® design. Retrieved from http://www.knowledgenetworks.com/ganp/docs/KnoweldgePanel-Summary-Design-Description-041009.pdf
21. Elbasha, E. H., Dasbach, E. J., & Insinga, R. P. (2007). Model for assessing human papillomavirus vaccination strategies. Emerging Infectious Diseases, 13(1), 28-41.
22. Fiebig, D. G., Haas, M., Hossain, I., Street, D. J., & Viney, R. (2009). Decisions about Pap tests: What influences women and providers? Social Science Medicine, 68, 1766-1774.
23. Finkelstein, E. A., and Brown, D. S., Brown, D. R., & Buchner, D. M. (2008). A randomized study of financial incentives to increase physical activity among sedentary older adults. Preventive Medicine, 47, 182-187.
24. Fleurence, R. L., and Dixon, J. M., Milanova, T. F., & Beusterien, K. M. (2007). Review of the economic and quality-of-life burden of cervical human papillomavirus disease. American Journal Obstetrics and Gynecology, 196, 206-212.
25. Flynn, T. N., and Louviere, J. J., Peters, T. J., & Coast, J. (2007). Best-worst scaling: What it can do for health care research and how to do it. Journal of Health Economics, 26, 171-189.
26. Greene, W. H, & Hensher, D. A. (2003). A latent class model for discrete choice analysis: Contrasts with mixed logit. Journal of Transportation Research Part B: Methodological, 37(8), 681-698.
27. Hariri, S., and Unger, E. R., Sernberg, M., Dunne, E. F., Swan, D., Patel, S., Markowitz, L. E. (2011). Prevalence of genital human papillomavirus among females in the United States, the national health and nutrition examination survey, 2003-2006. Journal of Infectious Diseases, 204, 566-573.
28. Hensher, D. A., and Rose, J. M., & Greene, W. H. (2005). Applied choice analysis. Cambridge: Cambridge University Press.
29. Herrero, R. (2009). Human papillomavirus (HPV) vaccines: Limited cross-protection against additional HPV types. Journal of Infectious Disease, 199, 919-922.
30. Hole, A. R. (2008). Modelling heterogeneity in patients' preferences for the attributes of a general practitioner appointment. Journal of Health Economics, 27, 1078-1094.
31. Insinga, R. P., and Dasbach, E. J., & Elbasha, E. H. (2005). Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: Analytic framework and review of the literature. Pharmacoeconomics, 23, 1107-1122.
32. Jensen, M. E., Hartenbach, E., McElroy, J. A., Faerber, A., Havighurst, T., Kim, K. M., Bailey, H. H. (2009). Brief report: Measuring the attitudes of health care professionals in Dane County toward adolescent immunization with HPV vaccine. WMJ: Official Publication of the State Medical Society of Wisconsin, 108, 203-205.
33. Jit, M., and Choi, Y. H., & Edmunds, W. J. (2008). Economic evaluation of human papillomavirus vaccination in the United Kingdom. British Medical Journals, 377, a769.
34. Johnson, F. R., and Banzhaf, M. R., & Desvousges, W. H. (2000). Willingness to pay for improved respiratory and cardiovascular health: A multiple-format, stated-preference approach. Health Economics, 9, 295-317.
35. Kahn, J. A., and Rosenthal, S. L., Jin, Y., Huang, B., Namakydoust, A., & Zimet, G. D. (2008). Rates of human papillomavirus vaccination, attitudes about vaccination, and human papillomavirus prevalence in young women. Obstetrics and Gynecology, 111, 1103-1110.
36. Kim, J. J. (2009). Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. British Medical Journals, 339, b3884.
37. Kim, J. J. (2010). Targeted human papillomavirus vaccination of men who have sex with men in the USA: A cost-effectiveness modelling analysis. Lancet Infectious Diseases, 10(12), 845-852.
38. Kim, J. J., & Goldie, S. J. (2008). Health and economic implications of HPV vaccination in the United States. New England Journal Medicine, 359, 821-832.
39. Krinsky, I., & Robb, A. L. (1986). On approximating the statistical properties of elasticities. Review of Economic Statistics, 68, 715-719.
40. Lacey, C. J., and Lowndes, C. M., & Shah, K. V. (2006). Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine, 24, S35-S41.
41. Leddy, M. A., and Anderson, B. L., Gall, S., & Schulkin, J. (2009). Obstetrician-gynecologists and the HPV vaccine: Practice patterns, beliefs, and knowledge. Journal of Pediatric and Adolescent Gynecology, 22, 239-246.
42. Liao, C. H., and Liu, J. T., Pwu, R. F., You, S. L., Chow, I., & Tang, C. H. (2009). Valuation of the economic benefits of human papillomavirus vaccine in Taiwan. Value in Health, 12(Suppl. 3), S74-S77.
43. Louviere, J., Hensher, D., & Swait, J. (2000). Stated choice methods: Analysis and application. Cambridge: Cambridge University Press.
44. Lu, B., Mukar, A., Castellsague, X., & Giuliano, A. R. (2011). Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: A systematic review and meta-analysis. BMC Infectious Diseases, 11, 13.
45. Marshall, D. A., and Johnson, F. R., Kulin, N. A., Ozdemir, S., Walsh, J. M., and Marshall, J. K., Phillips, K. A. (2009). How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Economics, 18(12), 1420-1439.
46. Mathur, M. B., and Mathur, V. S., & Reichling, D. B. (2010). Participation in the decision to become vaccinated against human papillomavirus by California high school girls and the predictors of vaccine. Journal of Pediatric Health Care, 24(1), 14-24.
47. McFadden, D. (1974). Conditional logit analysis of qualitative choice behavior. In P. Zarembka (Ed.), Frontiers in econometrics. New York, NY: Academic Press.
48. Miller, G. A. (1956). The magical number seven plus or minus two: Some limits on our capacity for processing information. Psychological Review, 63, 81-97.
49. Oteng, B., Marra, F., Lynd, L. D., Ogilvie, G., Patrick, D., & Marra, C. A. (2011). Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme. Sexually Transmitted Infections, 87(1), 52-57.
50. Paavonen, J., Naud, P., Salmeron, J., Wheeler, C. M., Chow, S.-N, Apter, D. et al. (2009). Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet, 374, 310-314.
51. Pacifico, D., & Yoo, H. (2013). LCLOGIT: A Stata command for fitting latent-class conditional logit models via the expectation-maximization algorithm. Stata Journal, 13(3), 625-639.
52. Poulos, C., Yang, J.-C., Levin, C., Van Minh, H., Glang, K. B., & Nguyen, D. (2011). Mothers' preferences and willingness to pay for HPV vaccines in Vinh Long Province, Vietnam. Social Science & Medicine, 73(2), 226-234.
53. Ready, R. C., and Champ, P. A., & Lawton, J. L. (2010). Using respondent uncertainty to mitigate hypothetical bias in a stated choice experiment. Land Economics, 86(2), 363-381.
54. Roden, R. B., Ling, M., & Wu, T. C. (2004). Vaccination to prevent and treat cervical cancer. Human Pathology, 35, 971-982.
55. Ryan, M., & Farrar, S. (2000). Using conjoint analysis to elicit preference for health care. British Medical Journal, 320, 1530-1533.
56. San Miguel, F., Ryan, M., & Amaya-Amaya, M. (2005). "Irrational" stated preferences: A quantitative and qualitative investigation. Health Economics, 14, 307-322.
57. Schiffman, M., Clifford, G, & Buonaguro, F. M. (2009). Classification of weakly carcinogenic human papillomavirus types: Addressing the limits of epidemiology at the borderline. Infectious Agents and Cancer, 4, 8.
58. Schwarz, T. F., Spaczynski, M., Schneider, A., Wysocki, J., Galaj, A., Perona, P. et al. (2009). Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine, 27, 581-587.
59. Smith, J. S., Lindsay, L., Hoots, B., Keys, J., Franceschi, S., Winer, R., Clifford, G. M. (2007). Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. International Journal of Cancer Prevention, 121(3), 621-632.
60. Train, K. (2003). Discrete choice methods with simulation. Cambridge: Cambridge University Press.
61. U.S. Cancer Statistics Working Group. (2012). United States cancer statistics: 1999-2008 incidence and mortality web-based report. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Atlanta, GA. Retrieved from www.cdc.gov/uscs. Accessed on December 12, 2012.
62. Viney, R., Lanscar, E., & Louviere, J. J. (2002). Discrete choice experiments to measure preferences for health and health care. Expert Review of Pharmacoeconomics and Outcomes Research, 2, 319-326.
63. Whitehead, J. C. (2005). Environmental risks and averting behavior: Predictive validity of jointly estimated revealed and stated behavior data. Environmental and Resource Economics, 32, 301-316.
64. Wordsworth, S., Ryan, M., & Waugh, N. (2001). Costs and benefits of cervical screening IV: Valuation by women of the cervical screening programme. Cytopathology, 12(6), 367-376.
65. World Health Organization (WHO). (2007). Cervical cancer, human papillomavirus (HPV), and HPV vaccines: Key points for policy-makers and health professionals. Geneva: WHO.
66. Zimet, G. D., and Mays, R. M., Sturm, L. A., Ravert, A. A., and Perkins, S. M., & Juliar, B. E. (2005). Parental attitudes about sexually transmitted infection: Vaccination for their adolescent children. Archives of Pediatric and Adolescent Medicine, 159, 132-137.